SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008.
  • 2
    Ferlay J, Shin HR, Bray F, Forman D, Mathers CD, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; Year. Available at: http://globocan.iarc.fr. 2010. Last accessed 8/17/2010.
  • 3
    World Health Organization Databank. WHO Statistical Information System. Geneva: World Health Organization; Year. Available at: http://www.who.int/whosis. 2010. Last accessed 2/16/2010.
  • 4
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. [published online ahead of print June 17, 2010].
  • 5
    United Nations Population Division. World Population Prospects, the 2008 Revision. New York: United Nations; Year. Available at: http://www.un.org/. 2008. Last accessed 10/30/2010.
  • 6
    Segi M. Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
  • 7
    DollR, PayneP, WaterhouseJAH, eds. Cancer Incidence in Five Continents. Vol I. Geneva: Union Internationale Contre le Cancer; 1966.
  • 8
    Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010; 11: 165-173.
  • 9
    Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008; 9: 730-756.
  • 10
    Jemal A, Center MM, Desantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1893-1907.
  • 11
    Mackay J, Jemal A, Lee NC, Parkin DM. The Cancer Atlas. Atlanta, GA: American Cancer Society; 2006.
  • 12
    Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas. 2001; 38: 103-113; discussion 113-116.
  • 13
    Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol. 2007; 8: 292-293.
  • 14
    Key J, Hodgson S, Omar RZ, et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control. 2006; 17: 759-770.
  • 15
    Althuis MD, Dozier JD, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005; 34: 405-412.
  • 16
    Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670-1674.
  • 17
    Cronin KA, Ravdin PM, Edwards BK. Sustained lower rates of breast cancer in the United States. Breast Cancer Res Treat. 2009; 117: 223-224.
  • 18
    Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116: 544-573.
  • 19
    Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 2009; 45: 1649-1653.
  • 20
    Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. 2009; 96: E1-E6.
  • 21
    Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008; 188: 641-644.
  • 22
    Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010; 341: c3620.
  • 23
    Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer. 2010; 126: 1187-1195.
  • 24
    ParkinDM, WhelanS, FerlayJ, StormH, eds. Cancer Incidence in Five Continents. Vol I to VIII. Cancer Base No. 7. Lyon: IARC Press; 2005.
  • 25
    Colditz GA, Sellers TA, Trapido E. Epidemiology-identifying the causes and preventability of cancer? Nat Rev. 2006; 6: 75-83.
  • 26
    Ito Y, Ioka A, Tanaka M, Nakayama T, Tsukuma H. Trends in cancer incidence and mortality in Osaka, Japan: evaluation of cancer control activities. Cancer Sci. 2009; 100: 2390-2395.
  • 27
    Kushi LH, Byers T, Doyle C, et al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006; 56: 254-281; quiz 313-314.
  • 28
    Anderson BO, Yip CH, Ramsey SD, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006; 12( suppl 1): S54-S69.
  • 29
    Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113( 8 suppl): 2221-2243.
  • 30
    Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1688-1694.
  • 31
    Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59: 366-378.
  • 32
    Garcia-Alvarez A, Serra-Majem L, Ribas-Barba L, et al. Obesity and overweight trends in Catalonia, Spain (1992-2003): gender and socio-economic determinants. Public Health Nutr. 2007; 10: 1368-1378.
  • 33
    Martin JJ, Hernandez LS, Gonzalez MG, Mendez CP, Rey Galan C, Guerrero SM. Trends in childhood and adolescent obesity prevalence in Oviedo (Asturias, Spain) 1992-2006. Acta Paediatr. 2008; 97: 955-958.
  • 34
    de Kok IM, Wong CS, Chia KS, et al. Gender differences in the trend of colorectal cancer incidence in Singapore, 1968-2002. Int J Colorectal Dis. 2008; 23: 461-467.
  • 35
    Chu KC, Tarone RE, Chow WH, Hankey BF, Ries LA. Temporal patterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990. J Natl Cancer Inst. 1994; 86: 997-1006.
  • 36
    Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg. 2002; 89: 1557-1562.
  • 37
    Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001; 37: 1659-1667.
  • 38
    Ferrari P, Jenab M, Norat T, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer. 2007; 121: 2065-2072.
  • 39
    Giovannucci E, Wu K. Cancers of the colon and rectum. In: SchottenfeldD, FraumeniJFJr, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006;809-829.
  • 40
    BoyleP, LevinB, eds; World Cancer Report 2008. Lyon, France: World Health Organization. International Agency for Research on Cancer; 2008.
  • 41
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328: 1365-1371.
  • 42
    Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-669.
  • 43
    Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med. 1995; 123: 904-910.
  • 44
    Lambert R, Sauvaget C, Sankaranarayanan R. Mass screening for colorectal cancer is not justified in most developing countries. Int J Cancer. 2009; 125: 253-256.
  • 45
    Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
  • 46
    Mackay J, Eriksen M, Shafey O. The Tobacco Atlas. 2nd ed. Atlanta, GA: American Cancer Society; 2006.
  • 47
    Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis. 2004; 8: 1045-1057.
  • 48
    Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull. 2003; 68: 71-94.
  • 49
    Thun MJ, Hannan LM, Adams-Campbell LL, et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008; 5: e185.
  • 50
    Spitz M, Wu X, Wilkinson A, Wei Q. Cancer of the Lung. Oxford, UK: Oxford University Press; 2006.
  • 51
    Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008; 3: 819-831.
  • 52
    Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer. 2010; 126: 1454-1466.
  • 53
    Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005; 116: 963-971.
  • 54
    Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003; 362: 847-852.
  • 55
    Peto R, Lopez AD, Boreham J, Thun M. Mortality From Smoking in Developed Countries 1950-2000. 2nd ed. Revised June 2006. Available at: http://www.ctsu.ox.ac.uk/∼tobacco/SMK_All_PAGES.pdf. International Union Against Cancer (UICC). Geneva: Switzerland. 2006. Last Accessed 7/1/2010.
  • 56
    Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
  • 57
    Harris JE. Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80. J Natl Cancer Inst. 1983; 71: 473-479.
  • 58
    Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs-2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2007.
  • 59
    Shafey O, Eriksen M, Ross H, Mackey J The Tobacco Atlas. 3rd ed. Atlanta, GA: American Cancer Society; 2009.
  • 60
    World Health Organization. WHO Framework Convention on Tobacco Control. Available at: http://whqlibdoc.who.int/publications/2003/9241591013.pdf. Accessed March 9, 2010.
  • 61
    Bock CH, Schwartz AG, Ruterbusch JJ, et al. Results from a prostate cancer admixture mapping study in African-American men. Hum Genet. 2009; 126: 637-642.
  • 62
    Miller DC, Zheng SL, Dunn RL, et al. Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res. 2003; 63: 3486-3489.
  • 63
    Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53: 171-184.
  • 64
    Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007; 99: 1881-1887.
  • 65
    Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010; 46: 3040-3052.
  • 66
    Kvale R, Moller B, Angelsen A, et al. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Epidemiol. 2010; 34: 359-367.
  • 67
    Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
  • 68
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 69
    Platz EA, Giovannucci E. Prostate cancer. In: SchottenfeldD, FraumeniJFJr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 1151-1165.
  • 70
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 3030-3044.
  • 71
    Bertuccio P, Chatenoud L, Levi F, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009; 125: 666-673.
  • 72
    Chen J, Bu XL, Wang QY, Hu PJ, Chen MH. Decreasing seroprevalence of Helicobacter pylori infection during 1993-2003 in Guangzhou, southern China. Helicobacter. 2007; 12: 164-169.
  • 73
    Kawakami E, Machado RS, Ogata SK, Langner M. Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children. Arq Gastroenterol. 2008; 45: 147-151.
  • 74
    Tkachenko MA, Zhannat NZ, Erman LV, et al. Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr. 2007; 45: 428-432.
  • 75
    Lee JK, Inoue M, Otani T, Iwasaki M, Sasazuki S, Tsugane S; JPHC Study Group. Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer. 2006; 118: 2315-2321.
  • 76
    Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45: 529-538.
  • 77
    Shin HR, Oh JK, Masuyer E, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010; 101: 579-585.
  • 78
    London WT, McGlynn KA. Liver cancer. In: SchottenfeldD, FraumeniFJJr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 763-786.
  • 79
    Ming L, Thorgeirsson SS, Gail MH, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology. 2002; 36: 1214-1220.
  • 80
    International Agency for Research on Cancer (IARC). Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 82. Lyon, France: International Agency for Research on Cancer; 2002.
  • 81
    El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007; 37( suppl 2): S88-S94.
  • 82
    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27: 1485-1491.
  • 83
    Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008; 48: 137-145.
  • 84
    Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101: 1348-1355.
  • 85
    World Health Organization. Vaccine-Preventable Diseases: Monitoring System 2009 Global Summary. WHO/UNICEF Coverage Estimates for 1980-2008, as of August 2009. Available at: http://www.who. int/immunization_monitoring/routine/immunization_coverage/en/index4.html. Accessed January 5, 2010.
  • 86
    Centers for Disease Control and Prevention (CDC). Implementation of newborn hepatitis B vaccination–worldwide, 2006. MMWR Morb Mortal Wkly Rep. 2008; 57: 1249-1252.
  • 87
    Turner PC, Sylla A, Gong YY, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet. 2005; 365: 1950-1956.
  • 88
    Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the latin america and Caribbean region. Vaccine. 2008; 26( suppl 11): L1-L15.
  • 89
    Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix–worldwide. Asian Pac J Cancer Prev. 2009; 10: 645-650.
  • 90
    Vizcaino AP, Moreno V, Bosch FX, et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer. 2000; 86: 429-435.
  • 91
    Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. Int Perspect Sex Reprod Health. 2009; 35: 147-154.
  • 92
    Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009; 360: 1385-1394.
  • 93
    Sankaranarayanan R. HPV vaccination: the promise & problems. Indian J Med Res. 2009; 130: 322-326.
  • 94
    Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
  • 95
    Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-1255.
  • 96
    Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd edition. Geneva: World Health Organization; 2000.
  • 97
    Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008; 21: 322-327.
  • 98
    Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005; 113: 456-463.
  • 99
    Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature beverages and foods and esophageal cancer risk–a systematic review. Int J Cancer. 2009; 125: 491-524.
  • 100
    Islami F, Pourshams A, Nasrollahzadeh D, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study. BMJ. 2009; 338: b929.
  • 101
    Wu M, Liu AM, Kampman E, et al. Green tea drinking, high tea temperature and esophageal cancer in high- and low-risk areas of Jiangsu Province, China: a population-based case-control study. Int J Cancer. 2009; 124: 1907-1913.
  • 102
    Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003; 95: 1404-1413.
  • 103
    Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009; 38: 27-57, vii.
  • 104
    Lee CH, Lee JM, Wu DC, et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer. 2005; 113: 475-482.
  • 105
    Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer. 2001; 85: 661-667.
  • 106
    Wu IC, Lu CY, Kuo FC, et al. Interaction between cigarette, alcohol and betel nut use on esophageal cancer risk in Taiwan. Eur J Clin Invest. 2006; 36: 236-241.
  • 107
    Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009; 101: 855-859.
  • 108
    Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol. 2008; 103: 2694-2699.
    Direct Link:
  • 109
    Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 2008; 122: 1118-1129.
  • 110
    El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007; 5: 17-26.
  • 111
    Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007; 42: 17-22.
  • 112
    Lu CL, Lang HC, Luo JC, et al. Increasing trend of the incidence of esophageal squamous cell carcinoma, but not adenocarcinoma, in Taiwan. Cancer Causes Control. 2010; 21: 269-274.
  • 113
    Sliverman D, Devesa S, Moore L, Rothman N. Bladder cancer. In: SchottenfeldD, FraumeniFJJr, eds. Cancer Epidemiology and Prevention. 3rd ed. Oxford: Oxford University Press; 2006: 1101-1027.
  • 114
    Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008; 44: 1345-1389.
  • 115
    Felix AS, Soliman AS, Khaled H, et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control. 2008; 19: 421-429.
  • 116
    Zaghloul MS, Nouh A, Moneer M, El-Baradie M, Nazmy M, Younis A. Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer. J Egypt Natl Canc Inst. 2008; 20: 168-174.
  • 117
    Hartge P, Wang SS, Bracci PM, Devesa SS, Holly EA. Non-Hodgkin lymphoma. In: SchottenfeldD, FraumeniJFJr, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 2006: 898-918.
  • 118
    Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992; 52( 19 suppl): 5432s-5440s.
  • 119
    Bahl S, Theis B, Nishri D, Marrett LD. Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control. 2008; 19: 1251-1258.
  • 120
    Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res. 1992; 52( 19 suppl): 5566s-5569s.
  • 121
    Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002; 94: 1204-1210.
  • 122
    Sriplung H, Parkin DM. Trends in the incidence of acquired immunodeficiency syndrome-related malignancies in Thailand. Cancer. 2004; 101: 2660-2666.
  • 123
    Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006; 118: 985-990.
  • 124
    Abdel-Fattah MM, Yassine OG. Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004). Eur J Cancer Prev. 2007; 16: 479-485.
  • 125
    Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol. 2009; 10: 321-322.
  • 126
    Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988; 48: 3282-3287.
  • 127
    Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009; 18: 541-550.
  • 128
    International Agency for Research on Cancer. Betal Quid and Areca Nut Chewing and Some Areca Nut Derived Nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 85. Lyon, France: IARC; 2004.
  • 129
    International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 89. Lyon, France: IARC; 2007.
  • 130
    D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009; 199: 1263-1269.
  • 131
    US Department of Health and Human Services. A Surgeon General's report on the Health Consequences of Smoking. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Office of Smoking and Health; 2004.
  • 132
    Danaei G, Vander Hoorn S, Lopez AD, Murray C, Ezzati M; Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366: 1784-1793.
  • 133
    Jayalekshmi PA, Gangadharan P, Akiba S, Nair RR, Tsuji M, Rajan B. Tobacco chewing and female oral cavity cancer risk in Karunagappally cohort, India. Br J Cancer. 2009; 100: 848-852.
  • 134
    Wen CP, Tsai MK, Chung WS, et al. Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking. Cancer Causes Control. 2010; 21: 1427-1435.
  • 135
    Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC. The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med. 2002; 31: 213-219.
  • 136
    Garavello W, Bertuccio P, Levi F, et al. The oral cancer epidemic in central and eastern Europe. Int J Cancer. 2010; 127: 160-171.
  • 137
    Mayne ST, Morse D, Winn D. Cancers of the oral cavity and pharynx. In: SchottenfeldD, FraumeniJFJr, eds. Cancer Epidemiology and Prevention. 3rd ed. Oxford: Oxford University Press; 2006: 674-696.
  • 138
    DeLancey JO, Thun MJ, Jemal A, Ward EM. Recent trends in Black-White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2908-2912.
  • 139
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26: 612-619.
  • 140
    Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999)-recent trends and regional variation. Oral Oncol. 2006; 42: 586-592.
  • 141
    Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119: 2620-2623.
  • 142
    Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol. 2003; 39: 31-36.
  • 143
    Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer. 2005; 103: 1843-1849.
  • 144
    Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010; 11: 781-789.
  • 145
    CuradoMP, EdwardsBK, ShinHR, et al, eds. Cancer Incidence in Five Continents. Vol IX. IARC Scientific Pub. No. 160. Lyon, France: IARC; 2007.
  • 146
    Parkin DM, Whelan S, Ferlay J, Bah E, Hamdi-Cherif M. Cancer in Africa. IARC Scientific Pub. No. 153. Lyon, France: IARC Press; 2003.
  • 147
    Yu MC. Nasopharyngeal cancer. In: SchottenfeldD, FraumeniJFJr, eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 620-626.
  • 148
    Klein G. Nasopharyngeal carcinoma (NPC) is an enigmatic tumor. Semin Cancer Biol. 2002; 12: 415-418.
  • 149
    Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1765-1777.
  • 150
    Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974; 34: 1189-1191.
  • 151
    Henle W, Henle G. The cause of infectious mononucleosis. A review. In: BriggsPM, De-TheG, PayneLM, eds. Oncogenesis and Herpes Viruses. Lyon, France: IARC; 1972: 269-274.
  • 152
    Melbye M, Ebbesen P, Levine PH, Bennike T. Early primary infection and high Epstein-Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma. Int J Cancer. 1984; 34: 619-623.
  • 153
    Jia WH, Huang QH, Liao J, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer. 2006; 6: 178.
  • 154
    Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer. 2003; 103: 680-685.
  • 155
    Luo J, Chia KS, Chia SE, Reilly M, Tan CS, Ye W. Secular trends of nasopharyngeal carcinoma incidence in Singapore, Hong Kong and Los Angeles Chinese populations, 1973-1997. Eur J Epidemiol. 2007; 22: 513-521.
  • 156
    Hsu C, Shen YC, Cheng CC, Hong RL, Chang CJ, Cheng AL. Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: implication from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev. 2006; 15: 856-861.
  • 157
    Sun LM, Epplein M, Li CI, Vaughan TL, Weiss NS. Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol. 2005; 162: 1174-1178.
  • 158
    Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R. Classic kaposi sarcoma: epidemiology and risk factors. Cancer. 2000; 88: 500-517.
  • 159
    Oettle AG. Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes. Acta Unio Int Contra Cancrum. 1962; 18: 330-363.
  • 160
    Cook-Mozaffari P, Newton R, Beral V, Burkitt DP. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998; 78: 1521-1528.
  • 161
    Hutt MS. The epidemiology of Kaposi's sarcoma. Antibiot Chemother. 1981; 29: 3-11.
  • 162
    [no authors listed]. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993; 269: 729-730.
  • 163
    International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000; 92: 1823-1830.
  • 164
    Schulz TF. KSHV (HHV8) infection. J Infect. 2000; 41: 125-129.
  • 165
    Sitas F, Carrara H, Beral V, et al. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med. 1999; 340: 1863-1871.
  • 166
    Chokunonga E, Levy LM, Bassett MT, et al. Aids and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS. 1999; 13: 2583-2588.
  • 167
    Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000; 82: 1585-1592.
  • 168
    FerlayJ, BrayF, PisaniP, ParkinDM, eds. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.